For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
0
views
5
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      119
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Engineered CARD11–PIK3R3 T‐cell therapies as weapons of cancer mass destruction

      research-article
      Author(s): 1 , 2 , 3 , , 1 , 3 ,
      Publication date (Electronic):
      Journal: MedComm
      Publisher: John Wiley and Sons Inc.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Garcia et al. discover a novel immunotherapy approach by engineering naturally occurring mutations in therapeutic T cells to strongly elevate anti‐tumor activity. The authors identify a gene fusion, CARD11–PIK3R3, to increase activator protein 1 and nuclear factor–κB signaling, interleukin‐2 production, and tumor death in vitro and in vivo

          .

          Related collections

          Most cited references5

          • Record: found
          • Abstract: not found
          • Article: not found

          AP-1: a double-edged sword in tumorigenesis.

          Robert Eferl, Erwin F. Wagner (2003)
          Article 0 comments Cited 577 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            CRISPR-engineered T cells in patients with refractory cancer

            Edward A Stadtmauer, Joseph Fraietta, Megan M. Davis … (2020)
            CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells to fight cancer. We report a first-in-human phase I clinical trial to test the safety and feasibility of multiplex CRISPR-Cas9 editing to engineer T cells in three patients with refractory cancer. Two genes encoding the endogenous T cell receptor (TCR) chains, TCRα ( TRAC ) and TCRβ ( TRBC ) were deleted in T cells to reduce TCR mispairing and to enhance the expression of a synthetic, cancer-specific TCR transgene (NY-ESO-1). Removal of a third gene encoding PD-1 ( PDCD1 ), was performed to improve anti-tumor immunity. Adoptive transfer of engineered T cells into patients resulted in durable engraftment with edits at all three genomic loci. Though chromosomal translocations were detected, the frequency decreased over time. Modified T cells persisted for up to 9 months suggesting that immunogenicity is minimal under these conditions and demonstrating the feasibility of CRISPR gene-editing for cancer immunotherapy.
            Article 0 comments Cited 508 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Naturally occurring T cell mutations enhance engineered T cell therapies

              Julie Garcia, Jay Daniels, Yujin Lee … (2024)
              Article 0 comments Cited 5 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Min Wu: minwoo2022@126.com
                Yongye Huang: huangyongye88@163.com
                Journal
                Journal ID (nlm-ta): MedComm (2020)
                Journal ID (iso-abbrev): MedComm (2020)
                Journal ID (doi): 10.1002/(ISSN)2688-2663
                Journal ID (publisher-id): MCO2
                Title: MedComm
                Publisher: John Wiley and Sons Inc. (Hoboken )
                ISSN (Electronic): 2688-2663
                Publication date (Electronic): 01 July 2024
                Publication date Collection: July 2024
                Volume: 5
                Issue: 7 ( doiID: 10.1002/mco2.v5.7 )
                Electronic Location Identifier: e628
                Affiliations
                [ 1 ] Key Laboratory of Bioresource Research and Development of Liaoning Province College of Life and Health Sciences Northeastern University Shenyang China
                [ 2 ] Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University Wenzhou China
                [ 3 ] Wenzhou Institute University of Chinese Academy of Sciences Wenzhou China
                Author notes
                [*] [* ] Correspondence

                Yongye Huang, Key Laboratory of Bioresource Research and Development of Liaoning Province, College of Life and Health Sciences, Northeastern University, Shenyang, China.

                Email: huangyongye88@ 123456163.com

                Min Wu, Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University, Wenzhou, China.

                Email: minwoo2022@ 123456126.com

                Article
                Publisher ID: MCO2628
                DOI: 10.1002/mco2.628
                PMC ID: 11215281
                PubMed ID: 38952574
                SO-VID: 889b189d-cacb-4093-b8c5-b12becc76f0f
                Copyright © © 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
                License:

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                Date revision received : 10 May 2024
                Date received : 17 March 2024
                Date accepted : 04 June 2024
                Page count
                Figures: 2, Tables: 0, Pages: 4, Words: 1779
                Funding
                Funded by: Construction Project of Liaoning Provincial Key Laboratory, China
                Award ID: 2022JH13/10200026
                Funded by: Fund of the Affiliated Xiangshan Hospital of Wenzhou Medical University
                Funded by: Wenzhou Institute University of Chinese Academy of Sciences
                Categories
                Subject: Highlight
                Subject: Highlight
                Custom metadata
                source-schema-version-number 2.0
                cover-date July 2024
                details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.5 mode:remove_FC converted:01.07.2024

                Data availability:

                Comments

                Comment on this article